DELHI, Apr 22, 2025 - (JCN Newswire via SeaPRwire.com) - Olympus Medical Systems India Pvt. Ltd. (OMSI), an Olympus Group company, today announces the successful inauguration of newly constructed washrooms at eight government schools across major locations in India. This milestone is part of OMSI’s corporate social responsibility (CSR) initiative, the Water, Sanitation, and Hygiene (WASH) Program. By actively supporting community well-being and education through long-standing projects, OMSI and Olympus Corporation (Olympus), remain dedicated to supporting the next-generation education in India.Inauguration Ceremony at Government Middle School, Aklimpur, in Sohna Block of Gurugram District of Haryana, IndiaThe WASH Program, a decade-long CSR project by OMSI, focuses on enhancing school infrastructure by constructing and renovating washrooms to ensure that students—especially girls—have access to clean and safe sanitation facilities. This initiative addresses critical challenges in sanitation, hygiene, and child health that directly impact education. Several reports highlight that one in four girls in India drop out of school due to inadequate toilet facilities, underscoring the vital importance of this initiative for promoting gender equality and educational continuity. Over its fiscal year which ended in March 2025, the 10th year since the program began, OMSI constructed washrooms in eight government schools across four major locations—Delhi NCR, Kolkata, Chennai, and Mumbai. —This initiative provides improved sanitation facilities for over 2,700 students and ensures better hygiene standards for the school communities. The inauguration for these schools took place in March 2025, attended by OMSI leaders, school headmasters, and other officials. Over the past decade, the company has contributed to creating hygienic learning environments for approximately 7,000 students across 30 schools through this program.Nutrition kits handed over by Naoshi Kikumoto,MD, OMSIAdditionally, OMSI’s Olympus Arogya Bachpan (Disease-Free Childhood) Program, provided health check-ups, distributed nutrition kits, and held awareness sessions on essential topics such as personal hygiene and safety for approximately 450 students across two schools. This program, initiated in 2018, aims to improve student well-being through hygiene education, child safety awareness, and health check-ups, helping to combat malnutrition and instill lifelong healthy habits. Since its establishment in 2009, OMSI has remained committed to enhancing health, hygiene, and awareness through these activities, positively impacting thousands of children across India and enabling them to pursue their education in a safe and hygienic environment. “We at Olympus believe that every child deserves the opportunity to grow up healthy and to receive a quality education. Through our CSR programs, we are proud to contribute to a brighter, healthier future for children and communities across India," said Naoshi Kikumoto, Managing Director, OMSI. Together with Olympus, OMSI will continue advancing global corporate citizenship to make people's lives healthier, safer, and more fulfilling across India and beyond. Olympus’ Other CSR activities in India:Beyond its ongoing efforts in areas of hygiene and sanitation, OMSI also played a crucial role in supporting India’s healthcare infrastructure. In its fiscal year which ended in March 2025, the company supported the Saairaam Cancer Foundation in Salem, Tamil Nadu, and JIPMER (Jawaharlal Institute of Postgraduate Medical Education and Research), Pondicherry, by donating a Laparoscopic System and contributing to ENT (ear, nose and throat) cancer screening initiatives, respectively. These efforts aim to enhance cancer awareness, early detection, and treatment in underserved regions. During the COVID-19 pandemic, in its fiscal year ended in March 2021 and 2022, OMSI supported Civil Hospital Gurgaon, with Antigen Test Kits, Viral Transport Medium Kits, canopy tents for testing camps, and rental vehicles for transporting samples and lab technicians. The company also donated a fully equipped ambulance, solar lights and other essentials to support the Earth Saviours Foundation. Furthermore, OMSI focused on strengthening infrastructure at Primary Healthcare Centers (PHCs) in remote areas across the country. It also provided basic sanitation facilities at government hospitals in severely affected regions lacking such services. About Olympus At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit https://www.olympus-global.com/ and follow our global X account: @Olympus_Corp. Also visit LinkedIn page of OMSI.For media inquiries, please contact:Sanjana GroverOlympus Medical Systems India Pvt Ltdsanjana.grover@olympus.comhttps://www.olympus.in/ Public Relations GroupOlympus CorporationGlobal-Public_Relations@olympus.comhttps://www.olympus-global.com/Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com Copyright 2025 JCN Newswire via SeaPRwire.com.
Singapore, April 21, 2025 – In an unprecedented move, Taiwan’s Commercial Court has issued a provisional injunction prohibiting the convening of the upcoming shareholders’ annual meeting of Sinotactful (TWSE: 5481), marking the first such case involving a publicly listed company in Taiwan. The decision has sent shockwaves through Taiwan’s corporate sector and drawn concern from investment circles in Singapore and across the region about judicial intervention in corporate governance.
This court order, a provisional status injunction, is not directed at an extraordinary general meeting but instead freezes a regularly scheduled annual general meeting (AGM) mandated by law for the re-election of directors—making it a legal first in Taiwan. Public records reveal that the injunction was filed by shareholders aligned with the market faction. Despite Sinotactful having a net asset value of approximately NT$2 billion (about SGD 80 million), the court approved the injunction with relatively low security bonds of NT$1.65 million and NT$2 million (about SGD 150,000 in total). This has effectively paralyzed a board whose term has already expired, delayed financial reporting, and forced the company to reorganize multiple meetings—causing tangible harm to its operations and investors at large.
The Core Issue: Balancing Public Interest and Proportionality
A company advisor for Sinotactful commented, “Although the court had issued its ruling earlier, it wasn’t delivered to the company until a week before the AGM, giving the company almost no time to notify shareholders, and catching the market off guard. Given that the legal proceedings are expected to take at least 1–2 years to reach a final decision, director elections could be delayed for a prolonged period, potentially disrupting market order and harming all shareholders. Even if the final judgment allows the company to proceed with board elections, damage from the old board’s decisions—or inaction—during this interim could be irreversible.”
Sinotactful has filed an appeal against the ruling and has tasked its audit committee with calling an extraordinary shareholders’ meeting in accordance with Taiwan’s Company Act and Securities and Exchange Act, in an effort to maintain basic corporate governance operations.
Corporate governance observers in Singapore believe the case exposes structural risks in how the Asia-Pacific region balances judicial intervention with corporate governance. One anonymous asset manager in Singapore remarked, “We support protecting shareholder rights, but if courts can intervene with such a low threshold—impacting board composition and corporate operations—it may erode institutional investors’ confidence in the long-term stability of the market.”
Scholars have also raised concerns that Taiwan’s Commercial Court system may lack the institutional design to appropriately balance competing interests in shareholder disputes.
Taiwan’s Commercial Court currently operates under a two-level, two-instance system, but with only one Commercial Court staffed by three judges. Once a decision is made, the only path to appeal is through the Supreme Court on the basis of legal errors. However, the Supreme Court rarely makes direct rulings and instead tends to remand cases back to the same Commercial Court for reconsideration. This often means the original three judges may review their own decision, with no external oversight. If such rulings affect the rights of thousands of shareholders and market confidence, having them determined by a small panel with limited checks could trigger regional contagion risks.
Given Taiwan’s pivotal role in the global semiconductor and high-tech supply chain, whether this incident will affect foreign investors’ trust in its financial governance remains to be seen. One thing, however, is certain—what may appear to be an internal corporate dispute has already prompted regional investors to reflect: When the court steps into the boardroom, who safeguards the stability of the market?
Dubai, UAE – April 22, 2025 – (SeaPRwire) – Avenix Fzco has introduced Pivozon, an advanced EA designed for XAU/USD traders who prefer the structure and discipline of H1-based swing trading. There’s a noticeable shift in the forex trading world. A growing number of traders are moving to higher timeframes, embracing swing trading strategies that focus on patience and precision over rapid trades. This change reflects a growing desire for sustainable trading practices that align with longer-term market movements and help reduce the emotional strain of fast-paced decision-making.
Why Traders Prefer Higher Timeframes
Trading on higher timeframes, like the H1 (hourly) or D1 (daily) charts, offers clear benefits:
Less Market Noise: Shorter timeframes often exaggerate market volatility. Higher timeframes filter out this noise, making real trends easier to spot.
Better Decision-Making: With more time to evaluate conditions, traders can avoid impulsive entries and plan with a clear head.
Reduced Stress & Increased Profitability: Slower-paced trading helps maintain emotional discipline while capturing bigger price moves with stronger setups. It also encourages a more methodical, strategic mindset over constant screen-watching.
Pivozon: Built for Higher Timeframe Trading
Supporting this shift is Pivozon, a trading bot developed by Avenix Fzco. Tailored specifically for the XAU/USD (Gold/US Dollar) pair on the H1 timeframe, it brings a swing trading mindset to automation, focusing on sustained market moves instead of short-lived spikes.
Key Features of Pivozon:
H1 Timeframe Focus: Trades in alignment with the natural flow of the gold market, focusing on trend reversals and sustained price movements rather than short-term fluctuations.
Structured Precision: Built with robust trading algorithms, Pivozon’s system executes calculated trades based on structured, rule-driven strategies, allowing traders to benefit from well-timed entries and exits.
Gold-Centric Optimization: Unlike multi-asset bots, Pivozon is fine-tuned for the behavior of gold, offering deeper insight and stronger performance in this specific market.
Automated Execution & 24/5 Market Monitoring: The system runs continuously, executing trades based on pre-set parameters while eliminating emotional trading decisions. Traders don’t need to monitor charts around the clock, Pivozon does it for them with reliable consistency.
The Future of Swing Trading
As trading grows more accessible and fast-paced, many are stepping back and finding value in slower, smarter strategies. Higher timeframes offer a clearer view and more time to act, not react. Pivozon fits right into this trend, an automated solution that supports a more thoughtful, measured trading experience.
About Pivozon
Pivozon is an advanced Expert Advisor (EA) designed for long-term forex trading, integrating structured technical analysis with automation for precise execution. For more details, visit https://pivozon.com/.
Media contact
Brand: Pivozon
Contact: Media tem
Email: support@pivozon.com
Website: https://pivozon.com/
SHANGHAI, Apr 22, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) has approved the Company’s application to remove the “B” marker from its stock short name, as the company has satisfied the requirements of the listing rules at the Stock Exchange. “We are very pleased that Everest Medicines has satisfied the market capitalization/revenue test under Rule 8.05(3) of the Listing Rules and successfully removed the 'B' marker - a significant milestone for the Company in the capital markets that could lead to wider investor participation.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "Moving forward, we will continue to deepen our 'dual-engine strategy', enhancing our commercial excellence and advance our first-in-class and best-in-class assets with global rights to maximize synergies. With global rights to EVER001, we will actively explore partnership opportunities outside of China to leverage international expertise and optimize commercial value, while further enhancing Everest’s global visibility and presence. Everest will leverage its established efficient commercial platform to solidify our position in key therapeutic areas, advance innovation on our mRNA platform, and strive to become a leading biopharma in the Asia-Pacific region by 2030.The removal of the “B” marker reflects a comprehensive evaluation of Everest Medicines’ robust R&D pipeline, commercialization capabilities, and overall business fundamentals. Listed on the Stock Exchange in October 2020, Everest has adopted a “dual-engine” strategy, focusing on high-value therapeutic areas while striving to develop first-in-class or best-in-class innovative treatments. The company has established a strong and synergistic platform across nephrology, infectious diseases, and autoimmune diseases, with three commercialized products already driving rapid revenue growth.According to the company’s 2024 financial results, total revenue reached RMB706.7 million, representing a 461% year-over-year increase and exceeding our revenue guidance of RMB700 million, and achieved commercial-level profitability for the full year of 2024.NEFECON®, as the only approved IgAN therapy in China, generated RMB353.4 million in revenue for the year, representing a year-over-year increase of 1,581%. NEFECON® was also included in China’s National Reimbursement Drug List (NRDL), effective January 1, 2025. As the first-in-class fluorocycline antibiotic, XERAVA® (eravacycline) maintained robust growth with generated RMB352.8 million in revenue in 2024, representing a 256% year-on-year increase. VELSIPITY® (etrasimod), a best-in-class therapy for autoimmune diseases, has been received regulatory approvals in Macau and Singapore, the product was subsequently commercially launched in December in Guangdong province under the “Hong Kong and Macau Medicine and Equipment Connect” policy. In parallel, New Drug Applications (NDAs) for VELSIPITY® have been officially accepted in both mainland China and Hong Kong in December 2024.EVER001, for which Everest holds global rights, delivered positive results from the preliminary analysis of our Phase 1b/2a trial and is progressing steadily through global development. EVM16, our personalized therapeutic mRNA cancer vaccine, completed first patient dosing in an investigator-initiated clinical trial (IIT) in March 2025. EVM14, our off-the-shelf tumor-associated antigen (TAA) vaccine, received Investigational New Drug (IND) approval from the U.S. FDA, and we plan to submit an IND application to China’s NMPA in the first half of this year. The in vivo CAR-T program is expected to achieve preclinical candidate milestone later this year. These programs are supported by our commercial-scale, GMP-compliant manufacturing facility in Jiashan, Zhejiang, which provides integrated R&D, production, and commercialization capabilities across mRNA and other pipeline platforms. Copyright 2025 ACN Newswire via SeaPRwire.com.
New York, NY – April 22, 2025 – (SeaPRwire) – Meerkat ($MERK), a community-driven meme token project enhanced by AI and Web3 utilities, continues its presale phase while expanding its ecosystem features. With live staking, accessible mini-games, and tools for meme creation, the project emphasizes usability and community engagement over hype.
Designed to blend the cultural appeal of meme tokens with functional applications, Meerkat aims to offer users a range of interactive features within a single platform. Its ecosystem combines staking options, gaming mechanics, and DAO-based governance in a multi-chain environment.
Key presale details
Early access: $MERK tokens are available during the presale phase ahead of public distribution
Multi-chain compatibility: Purchases are supported on Binance Smart Chain (BSC), Solana, and Base
Ethereum claiming: After the presale ends, users will be able to claim their tokens as ERC-20 on Ethereum
Staking available: Token holders can participate in staking through the platform
Ecosystem highlights
Staking: Active and available for presale participants
Mini-games: Telegram-based games offering in-platform engagement
The Burrow: An AI-powered feature for creating meme token concepts
Governance: Community-driven decision-making via a $MERK-based DAO
New: $MERK miniapp now live
Tap to earn: Simple games with point-based progression
Daily quests: Tasks and missions with unlockable rewards
Leaderboards and badges: Community recognition through ranks and achievements
Referral system: Invite functionality to increase engagement
Official Channels
X (Twitter): https://x.com/Meerkatwtf
Telegram: https://t.me/meerkatwtf (need to add unique link for telegram)
Instagram: https://www.instagram.com/meerkatwtf/
Media Contact
Brand: Meerkat Ecosystem
Contact: Media Relations Team
Email: support@meerkat.wtf
Website: https://www.meerkat.wtf
HONG KONG, Apr 22, 2025 - (ACN Newswire via SeaPRwire.com) – In recent years, with the launch of top-level design for nuclear medicines and the implementation of supporting policies, the domestic nuclear medicine industry has ushered in a golden period of development. According to the data analysis of BCC Research, there will be a growth in the global nuclear medicine market from $12.6 billion in 2023 to $21 billion by the end of 2029, with a compound annual growth rate (CAGR) of 8.29% during the forecast period from 2024 to 2029. Meanwhile, Medraysintell, a market intelligence agency specializing in radiotherapy and nuclear medicine, predicts that there will be a growth of about $30 billion in the global nuclear medicine market in 2030.As a leading nuclear medicine company in China, CIRC (01763.HK) recently disclosed its annual report for 2024 as of December 31st. In 2024, CIRC achieved a remarkable growth in revenue and net profit, which not only delivered a satisfactory answer on the performance level, but also showed a strong technical transformation capability in nuclear medicine research and development.Year-by-year growth facilitated nuclear medical equipment to become a new engineAccording to the financial data, CIRC achieved revenue of RMB 7.575 billion in 2024, with a year-on-year increase of 14.2%, and the net profit of RMB 880 million, with a year-on-year increase of 13.3%.From the perspective of branch business, all fields have blossomed in an all-round way. As the core pillar of the company, the nuclear medicine business achieved revenue of RMB 4.168 billion, accounting for 55% of the total revenue. Among them, the income of imaging diagnosis and therapeutic radiopharmaceuticals increased by 4.1% year-on-year, and the distribution of medical centers all over the country achieved remarkable results. The income of Technetium-labeled medicines increased by 8.7% year-on-year. The breath test business continued to maintain a stable high market share, achieving revenue of RMB 2.35 billion, by a year-on-year increase of 1.1%.It is worth noting that in 2024, CIRC accelerated the localization of high-end radiotherapy equipment, and nuclear medical equipment and related services became the new engine of growth, with revenue reaching RMB 1.223 billion, a year-on-year increase of 31.0%. The new generation of Precision radiation therapy planning system was successfully approved for medical device registration certificate, and the world’s first spiral tomotherapy system, Tomo C, was delivered to Shandong Cancer Hospital for installation, which was successfully selected intothe 2024 high-end medical equipment promotion and application project of two ministries and commissions (Ministry of Industry and Information Technology/National Health Commission) and Tianjin First (Set) Major Technical Equipment Promotion and Application Guidance Catalog (Version 2024), with sales during the year leading in the domestic market.CIRC recorded RMB 716.1 million in revenue from radioactive source products, representing a year-on-year increase of 22.2%. Gamma knife source and non-destructive testing radioactive source continued to maintain a stable and high market share. CNNC Qinshan Isotope successfully obtained the Class A radiation safety license, and the cobalt-60 radioactive source production line delivered 2 million curies.40-year solid accumulation in nuclear technology laid a solid foundationAs the main body of the nuclear technology application industry of CNNC, CIRC has been accumulated in the industry for over 40 years, forming a “6+N” industrial layout with six major businesses as the core, including nuclides, nuclear medicines, nuclear medical equipment, integrated solution for nuclear medicine, radioactive source and application, and irradiation application. During the Reporting Period, CIRC achieved 224 patent authorizations, with a total of 969 valid patents, and continued to maintain the leading position of the R&D investment intensity in the industry.In the field of nuclear medicine research and development, CIRC has demonstrated a strong technical capability from research results turned into technologies. Sodium fluorine-18 injection obtained the drug registration certificate from the National Medical Products Administration and was approved for marketing, filling the market gap of PET diagnostic imaging agent in the field of bone imaging in China. Iodine-131-MIBG injection is close to the end of Phase III clinical trial. After the drug is launched, it will provide a new diagnostic method for neuroendocrine tumors such as pheochromocytoma and neuroblastoma. It is worth noting that CIRC has proactively laid out integrated diagnosis and treatment drugs, and the research and development of Lutetium-177oxyoctreotide injection is progressing smoothly, marking a strategic upgrade from simple diagnosis to precise diagnosis and treatment.In addition to stabilizing the base of nuclear medicine, CIRC has gradually increased its emphasis on nuclear medical equipment. According to the sales data in recent years, the income of nuclear medical equipment has steadily increased. In 2024, a new generation of Gamma Knife was approved, which integrated CBCT image guidance, six-dimensional bed auto-correction, and other intelligent technologies, and the treatment efficiency was improved by 30%. In the Class A large-scale medical equipment market, CIRC occupies an absolute dominant position through its holding subsidiary, CNNC ACCURAY. In February this year, 19 of the 28 high-end radiotherapy equipment in the second round of Class A large-scale medical equipment licensing list released by the National Health Commission came from CNNC ACCURAY, accounting for 68% of the market. It is worth noting that the breakthroughs in the fields of Cobalt-60-based Stereotactic Therapy System also promote the localization of radiotherapy equipment.Facing the explosive growth of the nuclear medicine market, CIRC Accelerated Pharmaceutical Center continues to expand its nationwide network layout. In 2024, a new positron emission drug production line has been added in Lanzhou, with a total of 23 lines put into operation; Newly added Fuzhou Technetium Drug Production Line, with a total of 27 units put into operation. CIRC has built the first 10,000 Curie level lutetium-177 production line and a thousand level germanium-gallium [68Ge-68Ga] generator production line in the country, achieving a breakthrough in the localization of high-end nuclides.It is worth noting that CIRC has created a hierarchical innovation ecosystem through the "Parent-Subsidiary Collaboration" model. In 2024, its subsidiaries, CNNC HEADWAY (breath test) and CNNC Chengdu Gaotong (nuclide), were awarded the national level specialized, refined, and new "little giants" enterprise, bringing the total number of specialized, refined, and new enterprises under CIRC to 18. Among them, CNNC HEADWAY dominates the breath testing market with its integrated solution of "medicine box+instrument", while CNNC Chengdu Gaotong has become a benchmark in the field of nuclear technology application through its full chain layout of "Nuclide-Drug-Equipment". This innovative system, resembling an "Aircraft carrier battle group", provides sustainable momentum for the company's long-term growth.Expanding Development Space with Globalization LayoutAs the main force of CNNC Group's march towards people's life and health science and technology and the main channel for the transformation of advanced nuclear science and technology achievements, CIRC responds to the Group's "Overall&Coordination" internationalization strategy and the national "the Belt and Road" initiative, vigorously promotes the internationalization strategy and constantly expands overseas markets. By 2024, the export revenue will reach RMB 627 million, and the products will be exported to dozens of countries and regions such as Brazil, Peru, and Nigeria.At the beginning of this year, we successfully signed a contract for the supply of equipment for a million curies design source gamma irradiation station in Bangladesh. This is another equipment supply project for irradiation stations that has landed after winning the bid for the Bangladesh Institute of Nuclear Agriculture's design source gamma irradiation station project in 2024. After its completion and operation, the irradiation station will mainly serve the irradiation sterilization of medical products in Bangladesh, significantly improving the quality level and production processing capacity of local medical products, assisting the development of Bangladesh's medical industry, and benefiting local people's livelihoods.In Nigeria, CIRC successfully signed a contract for the overall supply of nuclear medical equipment, achieving the first successful landing of the Group's nuclear medical equipment overall supply project. In addition, CIRC actively expands into the ASEAN market and successfully exports cold chain drugs to Thailand; We have also signed strategic cooperation agreements with multiple entities in Brazil to support the signing of a memorandum of understanding on strategic cooperation in the field of nuclear technology applications between the National Atomic Energy Agency and Brazil.ConclusionAgainst the backdrop of policy support and sustained market demand, CIRC stated to focus on the "Do as the Demard of the Country" and further deepen the coordinated development of nuclear medicine and high-end equipment around the "Healthy China" strategic framework. According to its 2025 plan, key projects such as Qinshan Isotope Base, Phase I of Jiajiang Radioactive Source Base, and Phase I of North China Pharmaceutical Base will be promoted according to milestones, involving nuclide production, radioactive source manufacturing, and pharmaceutical supply chain layout. At the same time, CIRC will enhance its digital diagnosis and treatment service capabilities through the iteration of smart nuclear medicine projects, and plans to launch no less than 3 intelligent systems within this year.At the international level, CIRC will continue the market expansion strategy along the "the Belt and Road", rely on the existing business models such as radiation station equipment export, nuclear medical equipment overall solution output, focus on the cooperation in South America, Southeast Asia, the Middle East, North Africa and other regional markets, and further improve the global market penetration rate in the future or through localized cooperation.The management of the Company stated that in 2025, CIRC will continue to strengthen technological innovation, improve the modern industrial system, accelerate the cultivation and development of new quality productivity, continuously enhance core functions, improve core competitiveness, and accelerate the establishment of an internationally-renowned supply group of technology, product and service in isotope and radiation. Copyright 2025 ACN Newswire via SeaPRwire.com.
Luxembourg, Apr 21, 2025 - (ACN Newswire via SeaPRwire.com) - Moolec Science SA (NASDAQ:MLEC) ("The Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it has entered into a Business Combination Agreement (the "BCA") with Bioceres Group Limited ("Bioceres Group") and other related entities in an all-stock transaction (the "Business Combination"). Subject to the terms and conditions of the BCA, which was signed on April 17, 2025, several parties will transfer their respective holdings in Bioceres Group, Nutrecon LLC ("Nutrecon"), and Gentle Technologies Corp ("Gentle Tech", and together with Bioceres Group and Nutrecon, the "Contributed Entities"), resulting in an enlarged corporate structure with Moolec as the parent company. In exchange, Moolec will issue a combination of up to 87 million newly issued shares and 5 million warrants to the shareholders of the Contributed Entities, as more fully described below in the Timing and Approvals section.Federico Trucco, Bioceres Group's board member and CEO of Bioceres Crop Solutions Corp commented: "The need to accelerate agricultural innovation to address current and future challenges, such as enhancing on-farm profitability and reducing environmental impact, is increasingly evident. Molecular farming, as exemplified by Moolec Science, offers a compelling solution to the challenge of balancing productivity and sustainability. For instance, what soybean yield technology can rival the direct production of 300kg of animal protein from a 3-ton-per-hectare crop?" He then finished: "Moolec's recent transformational transaction represents the kind of bold action needed to drive radical change in agriculture. Integrating technologies and capabilities, along with a holistic perspective on agricultural evolution, are essential for moving beyond incremental improvements. Scale and visibility, both of which are key aspects of this transaction, are crucial to achieving this goal. Bioceres is enthusiastic to be part of a larger, more ambitious Moolec, one that expands its focus from science in food ingredients to a comprehensive ‘cradle-to-cradle' approach."Juan Sartori, Founder and Chairman of Union Group remarked: "This is not just a strategic alignment of businesses, it's the creation of a new kind of company for the 21st century. By combining science, scale, and sustainability, Moolec is positioned to lead a global transformation in how we produce food, materials, and energy. I'm proud to support this vision and the exceptional teams bringing it to life."Following the closing of the Business Combination, Moolec will become uniquely positioned in the agricultural value-chain, with a powerful and validated technology discovery and development engine that can address in a cost-competitive way multiple upstream and downstream needs. Moolec's new value proposition will be centered around modifying or improving seeds and microbes to positively impact the way we utilize land and water resources, while preserving and/or improving human health.Alejandro Antalich, Chairman of Synbio Powerlabs® added: "This combination marks a defining moment for the bioeconomy. By integrating next-gen ingredients, biological ag solutions, and deep-tech manufacturing capabilities under one roof, we are building a company with unmatched scientific depth and commercial reach. Together, we aim to accelerate the shift toward a more sustainable and resilient food system, one that works in harmony with nature, rather than against it."As stated in their most recent annual reports, the companies and brands, which will be controlled or co-controlled by Moolec at the closing of the Business Combination, manage a portfolio of more than 800 patents (or patent applications) and over 550 product registrations, which translates into more than half a billion dollars of goods and services sold in their last fiscal year, to customers in more than 50 different countries.José López Lecube, CFO and Director of Moolec commented: "This transformative transaction marks a new stage for Moolec, positioning the company for growth within a broader organization that facilitates synergies on multiple levels. Becoming part of a larger organization will enable cost efficiencies and significant revenue increase as well as product portfolio diversification. It will also enlarge our investor base, providing the company with new stakeholders who support Moolec's new and more diversified business."Finally, as reported Mr. Gastón Paladini will step down as Chief Executive Officer (CEO), Director and Chairman of the Board, effective immediately following Moolec's Extraordinary General Meeting ("EGM") to be held on April 22, 2025.Key highlights:Ingredient Innovation: Moolec will continue to develop its flagship molecular farming products such as Piggy Sooy™ and GLASO™, while integrating Mycofood™ under the Eternal® brand from Nutrecon.Biological Ag Expansion: Through Bioceres Group, Moolec will now offer upstream technologies for regenerative agriculture, including biological inputs and climate-resilient seeds like Rizobacter®, ProFarm®, and the HB4® trait.Advanced R&D and Services: Leveraging expanded infrastructure, Moolec will offer R&D, CDMO, and regulatory services under the Agrality® and Synbio Powerlabs® brands, which are controlled or co-controlled by Bioceres Group and Nutrecon, respectively.Emerging Tech & Equipment: The Company will also expand its reach into emerging technologies for grain and biomass transformation, especially in the biomaterials space, as well as new concepts on farm equipment, integrating material science, electric mobility, and autonomy. These emerging opportunities are being pursued by Gentle Tech and Bioceres Group subsidiaries.Operational Synergies: The Business Combination is expected to result in significant cost synergies and an integrated management structure, which will be presented at or prior to closing of the Business Combination.Timing and ApprovalsThe Business Combination was unanimously approved by the Board of Directors of all the entities participating in the deal. It is expected to close during the second quarter of 2025 or thereafter, and it is subject to finalizing Moolec's reverse stock split process and re-domicile to the Cayman Islands among other customary closing conditions and regulatory approvals. This includes the approval by Moolec's shareholders at a special meeting of shareholders of proposals relating to the Business Combination. Given that the transaction was originally proposed by about 70% of Moolec's current shareholders, the Company expects strong shareholder support for the Business Combination approval.The Business Combination will be consummated through an equity exchange. Bioceres Group's shareholders will surrender their share ownership in Bioceres Group and will receive in exchange up to 80,590,280 shares of Moolec. The shareholders of 100% of Nutrecon and 50% of Gentle Tech will surrender their ownership in these two entities and will receive in exchange 6,475,000 shares of Moolec and 5,000,000 warrants of Moolec at a strike price of $2.00 per warrant, subject to adjustment based on the results of the reverse stock split process.The intrinsic value of the exchange ratio and the $2 strike price of warrants represent both a compelling premium to Moolec's current stock price, and a unique opportunity to assemble one of the most formidable public companies in the agricultural industry.Description of Contributed Entities and AssetsThe Contributed Entities consist of Bioceres Group and its subsidiaries, Nutrecon and its subsidiaries and Gentle Tech and its subsidiaries.Bioceres GroupBioceres Crop Solutions Corp. (NASDAQ: BIOX)Fully integrated provider of crop productivity solutions, including patented technologies for seeds and microbial agricultural inputs, as well as next generation crop nutrition and protection solutions. The company developed HB4® technology, which confers tolerance to climate changes in soybeans and wheat by allowing these crops to tolerate drought and soil salinity conditions. It also owns and licenses more than 570 products with approximately 750 patents and patent applications in the United States, Canada, Brazil, Argentina and other countries.Bioceres Tech Services (Agrality® & Inmet)Agrality® is a global agricultural services provider catering to agro-industrial companies worldwide. Their comprehensive service offerings encompass seed manufacturing and R&D, field-testing, and regulatory capabilities, ensuring their clients receive end-to-end solutions. Agrality's key assets include advanced seed production facilities, enabling high-quality seed development and production.Inmet specializes in the bio-transformation of agro-industrial residues, offering sustainable solutions for waste management in the agricultural sector. They utilize innovative technologies to convert agricultural waste into valuable products. Additionally, Inmet is involved in the production and assessment of bioplastics, contributing to the development of eco-friendly alternatives to conventional plastics.Nutrecon (Synbio Powerlabs®)Headquartered in Helsinki, Finland, Synbio Powerlabs® is an innovative early-stage biotechnology company specialized in research, development, and production of sustainable fungi-derived ingredients. With state-of-the-art laboratories and a pilot-to-industrial scale precision fermentation facility, the company operates uniquely as both a Research and Technology Organization ("RTO") and a Contract Development and Manufacturing Organization ("CDMO"). This dual role enables Synbio Powerlabs® to seamlessly bridge the gap between cutting-edge biotechnology research and real-world industrial applications, accelerating the commercialization of novel bio-based products. Its flagship product line, marketed under the Eternal® brand, features a diverse portfolio of high-quality, sustainable ingredients derived from fungi, serving multiple industries and applications.Gentle Tech (G-FAS & Gentle Farming)A frontier tech company developing sustainable, autonomous agricultural equipment. Focused on reducing environmental impact through innovations in materials science, information technologies, and alternative energy to maximize efficiency and minimize the carbon footprint. The business model includes G-FAS (selling ultra-light weight harvesting heads directly to farmers) and Gentle Farming (developing machinery for autonomy and intelligent management).Forward Looking StatementsThis press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.Contact InformationPress & Media: comms@moolecscience.comInvestor Relations: ir@moolecscience.comSOURCE: Moolec Science SARelated Documents:Moolec Science Enters into Transformational Transaction Expanding Across Multiple Technology Platforms.pdf Copyright 2025 ACN Newswire via SeaPRwire.com.
